- The trend backdrop is active with a 12-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
MARKSANS
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Marksans Pharma Limited · Healthcare · Drug Manufacturers - General
Latest close
273.9 INR
6.0%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 31.9% above the Trend Line and sits at 93.9% of its 52-week range. The latest completed week returned 6.0%, after a 0.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 54/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal.
Setup score
63
out of 100
Latest Close
273.9 INR
7 Aug 2026
1W Return
6.0%
latest completed week
4W Return
0.5%
short-term follow-through
12W Return
32.0%
quarterly tape
Trend Breadth
23.1%
12 of 52 weeks active
Volume Ratio
0.5x
vs 13-week average
- No major top-level risk cluster is currently dominant.
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
6.0%
Latest completed week; four-week move 0.5%.
Indicator stack
54/63
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
54/100
31 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 31.9% above the Trend Line and sits at 93.9% of its 52-week range. The latest completed week returned 6.0%, after a 0.5% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9512-week average 0.74
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.95Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 0.5% over four weeks, 32.0% over 12 weeks, and 29.8% over one year. The current trend has remained active for 12 consecutive weeks.
Performance by holding period
Active trend streak12 weeks
Active weeks in one year12
Trend breadth23.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.92Latest activity-pressure read.
Pressure change-43.3%Four-week change in activity pressure.
Leadership40.47Latest relative-leadership reading.
RS change-7.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength77/100Blend of value, momentum, and quality. Underlying universe rank 24; rank 1 is best.
Value36/100Relative valuation strength. Underlying universe rank 65; rank 1 is best.
Quality90/100Profitability and accounting quality. Underlying universe rank 11; rank 1 is best.
Momentum83/100Medium-term price momentum. Underlying universe rank 18; rank 1 is best.
Growth41/100Revenue and earnings growth. Underlying universe rank 60; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework54/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 29.7x Price divided by trailing earnings.
- Price / sales
- 4.2x Market value relative to trailing revenue.
- EV / EBITDA
- 17.8x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 2.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 56.7% Gross profit retained from each unit of revenue.
- Operating margin
- 17.0% Operating profit retained from revenue.
- Free-cash-flow margin
- 11.1% Free cash flow generated from revenue.
- Return on invested capital
- 13.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 12.5% Latest one-year revenue growth.
- EPS growth
- 9.8% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 870.8% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.3% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment54/100
Weighted news tone is neutral across 31 relevant articles.
3 positive · 27 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-2.8%Distance below the 52-week high.
13-week volatility5.9%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher16 of 2610 weeks finished lower.
Best week+16.2%Week of 29 May.
Worst week-7.8%Week of 24 Jul.
Latest week+6.0%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains8
Flat weeks0
Modest losses7
Sharp losses3
Recent vol5.9%13-week weekly-return volatility.
Base vol5.2%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew4.2% / -3.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank48 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - General
4-week rank6 / 11
Group average2.2%
Trend breadth72.7%
Trend72.7%active weekly trend signals
MD81.8%positive activity pressure
RS72.7%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape61/100
Trend, activity pressure, participation, and risk combine to a 61/100 tape read.
Indicator analysis91/100Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.95; No reversal markers Factors71/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 44; Small Cap Core rank 67 SVQF54/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 730.5 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment54/100Weighted news tone is neutral across 31 relevant articles.
Marksans Pharma publishes notice for 34th annual general meeting Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 273.9 INR | 6.0% | 207.7 INR | 200.3 INR | 0.92 | 40.47 | 5.1M | On |
| 31 Jul 2026 | 258.4 INR | 4.9% | 204.3 INR | 199.3 INR | 1.15 | 34.34 | 5.1M | On |
| 24 Jul 2026 | 246.3 INR | -7.8% | 201.8 INR | 198.3 INR | 1.40 | 31.86 | 9.7M | On |
| 17 Jul 2026 | 267.1 INR | -1.9% | 199.6 INR | 197.5 INR | 1.61 | 40.08 | 6.9M | On |
| 10 Jul 2026 | 272.4 INR | 3.0% | 196.7 INR | 196.5 INR | 1.62 | 43.89 | 13.5M | On |
| 3 Jul 2026 | 264.5 INR | 3.3% | 194.1 INR | 195.4 INR | 1.58 | 39.72 | 1.3M | On |
| 26 Jun 2026 | 256.1 INR | -1.4% | 191.4 INR | 194.3 INR | 1.54 | 36.70 | 0 | On |
| 19 Jun 2026 | 259.7 INR | 2.9% | 189.2 INR | 193.2 INR | 1.69 | 39.16 | 2.4M | On |
| 12 Jun 2026 | 252.4 INR | 8.2% | 186.9 INR | 192.2 INR | 1.77 | 37.92 | 2.5M | On |
| 5 Jun 2026 | 233.2 INR | -5.3% | 184.9 INR | 191.1 INR | 1.86 | 28.91 | 1.7M | On |
| 29 May 2026 | 246.2 INR | 16.2% | 183.2 INR | 190.2 INR | 2.00 | 35.03 | 61.3M | On |
| 22 May 2026 | 211.9 INR | 2.1% | 181.1 INR | 189.1 INR | 1.85 | 15.34 | 13.8M | On |
| 15 May 2026 | 207.4 INR | 4.9% | 179.9 INR | 188.3 INR | 1.84 | 13.03 | 11.5M | Off |
| 8 May 2026 | 197.8 INR | 7.1% | 178.9 INR | 187.4 INR | 1.65 | 5.16 | 14.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.